Outcome of very high-risk patients treated by Sotrovimab for mild-to-moderate COVID-19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study)
Guillaume Martin‐Blondel, Anne‐Geneviève Marcelin, Cathia Soulié, Sofia Kaisaridi, Clovis Lusivika‐Nzinga, Céline Dorival, Laura Nailler, Anaïs Boston, Cléa Melenotte, Géraldine Gaube, Christophe Choquet, Roland Liblau, Fabrice Carrat, Youri Yordanov
Topics & Concepts
MedicineAsymptomaticCoronavirus disease 2019 (COVID-19)Internal medicineCohortPediatricsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Cohort studyDiseaseInfectious disease (medical specialty)COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCOVID-19 Impact on Reproduction